Filing Details

Accession Number:
0000886163-16-000201
Form Type:
4
Zero Holdings:
No
Publication Time:
2016-08-02 19:46:45
Reporting Period:
2016-08-01
Filing Date:
2016-08-02
Accepted Time:
2016-08-02 19:46:45
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
886163 Ligand Pharmaceuticals Inc LGND Pharmaceutical Preparations (2834) 770160744
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1223000 W John Kozarich 3911 Sorrento Valley Boulevard, Ste 110
San Diego CA 92121
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2016-08-01 200 $135.78 41,783 No 4 S Direct
Common Stock Disposition 2016-08-01 500 $137.60 41,283 No 4 S Direct
Common Stock Disposition 2016-08-01 200 $138.31 41,083 No 4 S Direct
Common Stock Disposition 2016-08-01 100 $139.51 40,983 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
Footnotes
  1. The sale reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on December 01, 2015, in accordance with Rule 10b5-1.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $135.66 to $135.89, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $137.16 to $137.94, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $138.19 to $138.43, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.